Appointment strengthens Element's board as the company continues to advance the future of precision medicine and AI-enabled drug discovery; executive promotions reflect growing maturity of the company
SAN DIEGO, CA (August 18, 2026) — Element Biosciences, Inc. today announced that Mikael Dolsten, M.D., Ph.D., has joined its board of directors. Dr. Dolsten brings more than 35 years of leadership in biomedical research and global healthcare to Element’s board, most recently serving as chief scientific officer and president of Worldwide Research, Development and Medical at Pfizer. During more than 16 years at Pfizer, Dr. Dolsten helped advance approximately 40 medicines and vaccines to approval.
“Mikael brings more than three decades of leadership experience across some of the world’s foremost biopharmaceutical R&D organizations, making him an outstanding addition to our board,” said Molly He, CEO and co-founder of Element Biosciences. “As Element enters its next phase of growth, his experience translating scientific innovation into medicines with global impact, and helping next-generation life science and AI-enabled companies realize their potential, will be invaluable.”
“Element has built an exceptional scientific and technological foundation, with enormous potential to advance the future of precision medicine,” said Dr. Dolsten. “I look forward to working with Molly, the board, and the management team as Element scales its impact and develops new solutions that deepen our understanding of biology and accelerate the discovery and development of transformative medicines.”
Dr. Dolsten has authored more than 160 scientific publications, is an elected member of the Royal Swedish Academy of Engineering Sciences and has advised governments and international organizations on public health and biomedical innovation.
As Element advances this growth trajectory, the company has also promoted two key leaders to further strengthen its executive team. Jeff Labbadia has been named chief supply chain officer, recognizing his leadership in building the company’s integrated global supply chain, sponsoring its successful ISO 13485 certification, and supporting development of the forthcoming AVITI Dx™ platform.
Element co-founder Matt Kellinger has been promoted to senior vice president, product strategy. In this role, he will help connect R&D innovation more directly with commercial execution and ensure that customer needs remain central to Element’s product strategy and R&D priorities.
About Element Biosciences, Inc.
Element Biosciences is pioneering the technologies that enable a deeper understanding of life. Our platforms capture biology in its full dimensionality—spanning genetic, molecular, and cellular insights—to unlock richer data and drive scientific breakthroughs. From foundational research to the discoveries that help shape diagnostic and therapeutic development, Element empowers scientists to advance the frontiers of biology and impact every corner of human health. To learn more about Element, please visit www.elementbiosciences.com and follow us on LinkedIn, X (Twitter), and Facebook.
Media Contact
Michael Sullivan
Media@elembio.com